Gilead eyes PBC expansion for Livdelzi on positive one-year data

Gilead's Livdelzi Shows Positive One-Year Data in PBC Phase III

Gilead Sciences announced positive 52-week data from its Phase III IDEAL study (NCT06060665) for Livdelzi (seladelpar) in primary biliary cholangitis (PBC). The trial demonstrated Livdelzi's ability to significantly normalize alkaline phosphatase (ALP) levels in 96 PBC patients with inadequately controlled disease, compared to placebo. ALP normalization is linked to reduced risk of liver transplant or death. The drug maintained a consistent safety profile, with no new concerns identified. These results support Gilead's strategy to broaden Livdelzi's use within the PBC indication.

• The Phase III IDEAL study, involving 96 PBC patients with inadequately controlled disease, successfully met its primary objective by demonstrating that Livdelzi significantly increased the proportion of patients achieving ALP normalisation after 52 weeks compared to placebo. This outcome is crucial as ALP normalisation is a key biomarker associated with a reduced risk of disease progression, liver transplant, or death in PBC.
• Livdelzi, a selective PPAR-δ agonist, maintained a consistent safety and tolerability profile throughout the 52-week study, aligning with observations from previous clinical trials. No new safety concerns were identified, reinforcing the drug's potential as a well-tolerated treatment option for patients who have an incomplete response or intolerance to the current standard of care, ursodeoxycholic acid (UDCA).
• These positive 52-week results from the IDEAL study, combined with interim 24-month data from the open-label ASSURE study showing 74% composite ALP normalisation, are expected to bolster Gilead's efforts to expand Livdelzi's market reach within the PBC indication. The company plans to present the full dataset at an upcoming medical congress and engage with global regulatory authorities to discuss these findings.

Livdelzi's Positive Phase III IDEAL Data in PBC

Recent clinical studies in primary biliary cholangitis have demonstrated significant advances in therapeutic options and outcome assessment strategies. These investigations span novel PPAR agonists, established therapies, and treatment optimization approaches, providing comprehensive insights into current PBC management.

• ELATIVE Trial (NCT04526665) - Elafibranor: Phase III study of this PPAR α/δ agonist showed biochemical response rates ranging from 18.8% to 86.7% depending on baseline ALP levels, with overall mean ALP reduction of -38.9% at week 52, and consistent 4.0-4.5% reduction in 15-year liver transplant/mortality risk regardless of biochemical response status

• RECAPITULATE Project - Obeticholic Acid: Italian multicenter study (n=747) demonstrated POISE response probabilities of 57% and normal range response of 20% by 42 months, with 17% treatment discontinuation rate primarily due to pruritus (36.9%) and higher discontinuation rates in cirrhotic patients

• Seladelpar Meta-Analysis: Systematic review of three RCTs (n=499) showed significant improvements in ALP normalization (RR: 21.12) and biochemical response (RR: 3.06), with reduced pruritus incidence but increased headache occurrence compared to placebo

• UDCA Response Predictors Study: Analysis of 132 PBC patients identified that 43.9% had incomplete UDCA response, with CK7⁺ hepatobiliary cells, copper deposition, ALP levels, total bile acids, and anti-GP210 antibodies serving as predictive biomarkers with AUC values ranging from 0.588 to 0.809

• Baricitinib Case Report: Single patient with incomplete response to standard therapies (UDCA, obeticholic acid, fenofibrate) achieved complete response and sustained ALP normalization with baricitinib treatment

Addressing Unmet Needs in Primary Biliary Cholangitis Treatment

Current Primary Biliary Cholangitis treatment faces several significant challenges despite recent therapeutic advances. Up to 40% of patients demonstrate inadequate response to ursodeoxycholic acid (UDCA), the established first-line therapy, creating substantial unmet medical needs for this patient population.

• Limited first-line efficacy: UDCA treatment shows suboptimal response rates, with up to 40% of patients failing to achieve adequate biochemical improvement, necessitating second-line therapeutic interventions

• Regulatory setbacks for established therapies: Obeticholic acid, previously approved as second-line therapy, recently lost its marketing authorization in the EU due to unfavorable risk-benefit balance, reducing available treatment options

• Treatment personalization challenges: Current approaches lack robust frameworks for personalizing therapy selection, making it difficult to optimize treatment strategies for individual patient characteristics and disease severity

• Access barriers to novel therapeutics: Despite FDA and EMA approval of new PPAR agonists (elafibranor and seladelpar), patient access to these effective second-line therapies remains limited in clinical practice

• Inadequate endpoint identification: Clinical practice lacks robust biomarkers and endpoints beyond alkaline phosphatase normalization to comprehensively assess treatment efficacy and guide therapeutic decisions

• Quality of life considerations: While newer agents like seladelpar show promise in reducing pruritus, addressing the full spectrum of quality of life impairments including fatigue remains challenging with current treatment paradigms

Navigating the Evolving PBC Treatment Landscape

Several PPAR-δ agonists are being investigated for PBC treatment alongside seladelpar, representing an emerging therapeutic class with shared mechanisms of action. The clinical development programs for these compounds employ diverse intervention models ranging from early-phase dose-escalation studies to pivotal phase 3 trials.

Seladelpar's Sustained Efficacy: A New Standard in PBC Care

The recent announcement of positive 52-week data for seladelpar in primary biliary cholangitis (PBC) marks a pivotal moment for patients living with this chronic liver disease. For the significant proportion of individuals who do not respond adequately to first-line ursodeoxycholic acid (UDCA), the availability of effective and well-tolerated second-line options is paramount. Seladelpar, a selective peroxisome proliferator-activated receptor-delta (PPAR-δ) agonist, has consistently demonstrated its ability to achieve alkaline phosphatase (ALP) normalization, a critical biochemical endpoint strongly correlated with improved long-term outcomes, including reduced risk of liver transplant or death. The 52-week data reinforces the durability of these improvements, which is essential for a lifelong condition.

Beyond biochemical markers, seladelpar also addresses the debilitating symptom of pruritus, a common and often severe complication of PBC. Studies indicate that seladelpar significantly reduces pruritus, offering a distinct advantage over some other second-line agents like obeticholic acid (OCA), which has been associated with dose-dependent pruritus and recently faced regulatory challenges. While the competitive landscape includes other promising PPAR agonists such as elafibranor, seladelpar's strong pruritus profile and consistent safety record position it as a compelling choice.

However, the evolving treatment paradigm for PBC necessitates a nuanced understanding of each therapy's place.

• Personalized Treatment: The array of second-line options underscores the move towards personalized medicine in PBC, where treatment decisions can be tailored based on individual patient profiles, symptom burden, and tolerability.

• Long-term Validation: While surrogate endpoints are valuable, ongoing long-term studies will continue to be crucial for confirming sustained clinical benefits and transplant-free survival, solidifying the drug's role over decades.

• Safety Vigilance: Despite a generally favorable safety profile in later trials, the historical observation of transient aminotransferase elevations in early studies highlights the importance of continued pharmacovigilance.

Ultimately, the sustained efficacy and favorable safety profile demonstrated by seladelpar over 52 weeks provide a robust foundation for its role in improving the lives of patients with PBC, offering a much-needed therapeutic advancement in a complex disease.